2026-06-10 · glp-1, ozempic, wegovy, mounjaro, zepbound, rebound weight gain, maintenance · 12 min read

How much weight will I regain after stopping Ozempic or Wegovy?

In the STEP-1 extension (Wilding 2022), adults who lost about 17 percent of body weight on semaglutide 2.4 mg regained roughly two-thirds of that loss within 12 months of stopping — landing about 12 months later at roughly 11 percent above their nadir weight, or net 5 to 6 percent below baseline. The pattern is consistent across STEP-4 (semaglutide) and SURMOUNT-4 (tirzepatide). Individual results vary; people who stopped abruptly with no behavioral plan regained the most, and people who paired the stop with structured nutrition and resistance training held meaningfully more of their loss.

Can I taper instead of stopping cold?

Yes. Tapering is now standard clinical practice for people coming off semaglutide or tirzepatide, even though the trial protocols mostly studied abrupt stops. A typical taper steps down to the prior dose every 4 to 8 weeks (for example, 2.4 mg to 1.7 mg to 1.0 mg to 0.5 mg over 16 to 32 weeks), with weekly weigh-ins and a hold at any step where weight or appetite rebounds. The taper does not eliminate regain — the biology still pulls toward the prior set point — but it gives lifestyle infrastructure time to absorb the appetite return.

Does Mounjaro or Zepbound have the same rebound after stopping?

Yes, with similar magnitude. SURMOUNT-4 (Aronne 2024) randomized adults who had lost about 21 percent on tirzepatide to either continue or switch to placebo for 52 more weeks. The continuation group kept losing (to about 25 percent total loss); the placebo group regained about 14 percentage points — landing back near their initial 6-month weight. The directional answer is the same as semaglutide: stopping a GLP-1 without ongoing lifestyle infrastructure or maintenance dosing produces substantial regain within 12 months.

Is maintenance dosing a thing?

It is increasingly common in clinical practice but not formally studied in long-term trials. Some obesity-medicine clinicians keep patients on a lower weekly dose (for example, semaglutide 0.5 to 1.0 mg or tirzepatide 2.5 to 5.0 mg) once goal weight is reached, or stretch the interval to every 10 to 14 days. The 2.4 mg semaglutide continuation arm of STEP-4 and the SURMOUNT-4 continuation arm both show that some ongoing GLP-1 exposure holds most of the loss. The honest limit: there are no published phase 3 trials of low-dose long-term maintenance, and insurance often will not cover it. Discuss it with your prescriber rather than self-tapering.

Will strength training and high protein protect me from regain?

Partially, yes — and these are the highest-leverage levers a person has after stopping. GLP-1 weight loss carries a higher-than-average share of lean tissue (roughly 25 to 40 percent of weight lost in some sub-analyses), and that lost muscle is what most directly lowers your post-loss TDEE and accelerates regain. Resistance training 2 to 4 times per week plus protein at 1.6 g per kilogram of body weight or higher rebuilds and protects that muscle, which closes part of the metabolic-adaptation gap. See the dedicated framework in our guide to muscle preservation.

What if my insurance stops covering my GLP-1?

First, do not stop cold without a plan — even an unplanned stop deserves a structured re-feed and a behavioral floor. Second, ask your prescriber whether a slow taper (over 16 to 32 weeks) or a switch to a lower-cost branded route (LillyDirect Zepbound vials at roughly $349 to $549 per month) is feasible while you appeal coverage. Third, treat compounded GLP-1s with caution — FDA safety communications have flagged dosing errors and sterility problems, and the legal scope for compounding narrowed in 2024 once semaglutide and tirzepatide left the shortage list. The full cost-and-coverage map is in our GLP-1 cost and insurance guide.

Rebound Weight Gain After Stopping GLP-1: What to Expect and How to Minimize It

Quick answer

Four honest realities to anchor any decision about stopping a GLP-1:

1. Appetite returns within weeks. The hunger suppression you have felt is a drug effect, and it fades on the same pharmacokinetic curve the drug itself does — roughly 4 to 6 weeks for semaglutide, slightly faster for tirzepatide. The “I forgot to eat lunch” feeling stops first; food noise comes back next.
2. Glycogen and water return immediately. The first 5 to 8 pounds back on the scale in the first 2 to 4 weeks is mostly glycogen-bound water and gut-content normalization, not fat. This is not “regaining everything in a month” — it is your body returning to its normal hydration baseline.
3. Fat regain happens over months, not weeks. True fat regain follows the calorie surplus that appetite return creates, which builds gradually as portions creep up. Most regain across STEP-4, the STEP-1 extension, and SURMOUNT-4 lands in months 3 through 12.
4. About two-thirds of lost weight typically returns within 12 months without continued treatment or strong lifestyle anchoring. That is the central number from the STEP-1 extension and is consistent across the GLP-1 trial program.

The good news: each of those numbers is an average across people who mostly stopped without a structured plan. Planned tapering, resistance training, high-protein eating, and (when available) maintenance dosing each meaningfully change the curve.

Who this is for / not for

Good fit if:

• You are currently on semaglutide (Wegovy), tirzepatide (Zepbound), Ozempic, or Mounjaro and considering stopping or tapering.
• You are weighing whether to start a GLP-1 and want to understand the long-term commitment honestly.
• You stopped a GLP-1 in the past, regained, and want a framework for restarting with a better plan this time.
• You are post-bariatric on an adjunct GLP-1 and approaching a decision about discontinuation.

Not a fit if:

• You have type 2 diabetes and the GLP-1 is part of your glycemic-control regimen. Do not stop without your endocrinologist’s input — rebound hyperglycemia is a real and faster problem than weight regain. See our diabetes and weight loss guide for the broader picture.
• You are experiencing a medical reason to stop urgently (pancreatitis, severe gastroparesis, planned pregnancy in the near term, intolerable side effects). Those decisions are clinical, not lifestyle, and should be handled with your prescriber on a faster timeline than this article assumes.
• You are looking for a “how to keep the weight off without ever taking the drug again” guarantee. The trial evidence is clear that no behavioral plan fully reproduces the biological effect of ongoing GLP-1 therapy. The behavioral plan dramatically reduces the regain — it does not erase it.

What the trials actually show

Three trials anchor the rebound conversation.

STEP-1 extension (Wilding 2022). The original STEP-1 trial showed about 14.9 percent average body-weight loss over 68 weeks on semaglutide 2.4 mg. The 1-year off-treatment extension followed participants after the drug stopped. Within 12 months of discontinuation, participants regained roughly two-thirds of their lost weight, landing at a net loss of approximately 5.6 percent versus baseline. Cardiometabolic improvements (blood pressure, lipids, A1c) also reverted toward baseline. This is the canonical “two-thirds back” number you see referenced everywhere.

STEP-4 (Rubino 2021). A randomized continuation-versus-stop design. After 20 weeks of open-label semaglutide titration to 2.4 mg, participants were randomized either to continue or to switch to placebo for 48 more weeks. The continuation arm kept losing (to about 18 percent total loss); the placebo arm regained about 7 percentage points. The pattern was directionally identical to the STEP-1 extension, on a shorter horizon, in a controlled setting.

SURMOUNT-4 (Aronne 2024). The tirzepatide equivalent of STEP-4. After 36 weeks of open-label tirzepatide titration (mean loss about 21 percent), participants were randomized to continue tirzepatide or switch to placebo for 52 more weeks. The continuation arm kept losing (to about 25 percent total loss); the placebo arm regained roughly 14 percentage points, landing back near their initial 6-month weight. The bigger absolute regain in SURMOUNT-4 reflects the bigger absolute loss tirzepatide produces — the proportional regain is broadly comparable to STEP-4.

The directional read across all three: continuing the medication maintains or extends the loss; stopping produces substantial regain on a 6 to 12 month horizon, regardless of which GLP-1 was used.

Why your body regains

The regain curve is not a behavioral failure. It is the predictable output of biology that defended a higher weight throughout your weight-loss phase and continues to do so when the appetite-suppressing drug is removed.

Set-point biology. Your body defends a previously held weight through coordinated changes in hunger hormones, satiety signals, and energy expenditure. After a sustained calorie deficit, leptin (the satiety hormone) falls disproportionately to fat mass, ghrelin (the hunger hormone) rises, and total daily energy expenditure sits roughly 10 to 15 percent below what predictive equations expect for your new weight. The GLP-1 was masking that signal pharmacologically. When the drug clears, the underlying signal does not — it has been there the entire time. For the underlying mechanism, see set point theory and weight loss. Stopping a GLP-1 without a maintenance plan reproduces the same loss-and-regain pattern the body has defended against in every prior diet — see yo-yo dieting and weight cycling for the cumulative cost of repeating that cycle and the five-lever framework for breaking it.

Leptin and ghrelin rebound. Sumithran 2011 measured hunger and satiety hormones for a full year after a 10 percent weight loss in a non-GLP-1 cohort and found persistent appetite-stimulating changes through month 12. Hall 2022’s review of long-term regain biology shows the same pattern across diet, surgery, and medication: the hormonal pressure toward eating more does not normalize at the new lower weight on any meaningful timescale.

Water and glycogen vs fat — different timelines. Glycogen binds about 3 grams of water per gram of glycogen, and the first weeks of normal eating quickly restore both. That is why the scale almost always shows 5 to 8 pounds in the first 2 to 4 weeks even when fat is unchanged. True fat regain follows the calorie surplus that appetite return creates and builds over months. Reading early scale movement as “I’ve already regained” is one of the most common — and most destructive — interpretation errors people make in the first 6 weeks off the drug.

Tapering vs. stopping cold

The trial protocols mostly studied abrupt stops, but the actual clinical playbook in 2026 leans heavily toward tapering. The biology of taper is not magical — the body still pulls toward the higher set point — but a slow taper gives appetite return time to be matched by behavioral infrastructure rather than ambushing it.

A practical 8 to 16 week framework most obesity-medicine clinicians work from:

• Step down to the previous dose every 4 to 8 weeks. For semaglutide, that often looks like 2.4 mg → 1.7 mg → 1.0 mg → 0.5 mg over 16 to 32 weeks. For tirzepatide, 15 mg → 10 mg → 7.5 mg → 5 mg → 2.5 mg on a similar cadence.
• Hold at any step where weight rises more than 2 pounds on the 7-day rolling average across two consecutive weeks, or where food noise jumps back to pre-treatment levels.
• Weekly weigh-ins, not daily. The day-to-day noise is wider than the real underlying signal during a taper.
• Recheck baselines (food log, protein target, training schedule, sleep) before each dose drop, not after.

When stopping cold makes sense: an acute medical reason (pancreatitis, planned pregnancy), an insurance coverage cliff with no taper supply available, or a clinical decision to switch to a different agent. In every other case, taper is the default.

How to minimize regain

Five levers, in approximate order of leverage:

1. Build lifestyle infrastructure before stopping. Food log, weekly weigh-in habit, walking floor, and a consistent strength schedule should all be running for at least 8 weeks before the first dose drop. The window after the drug stops is not the time to learn how to track macros or fit lifting into a calendar. Pair the taper with a slow calorie ramp — 25 to 50 kcal per week added back toward maintenance — using the structured 5-step protocol in our reverse dieting guide, which has a dedicated GLP-1 section.
2. Hit protein at 1.6 g per kilogram of body weight or higher. GLP-1 weight loss carries a higher-than-average share of lean tissue, and that lost muscle is what most directly lowers post-loss TDEE. Protein is the single biggest dietary lever for protecting and rebuilding it. For practical gram targets by body weight and the protein-distribution rules, see protein intake for weight loss. Sub-target protein is also one of the main side effects of starting or stopping GLP-1 worth watching — alongside about 3 percent of STEP-1 patients who developed hair shedding 2 to 4 months into treatment, almost always driven by the rapid deficit and the appetite-suppressed protein and micronutrient intake the drug produces.
3. Keep (or start) resistance training 2 to 4 times per week. The strength signal tells the body to keep the muscle it has and rebuild what was lost. Without it, even adequate protein cannot fully prevent lean-mass loss. The full muscle-preservation framework — 2-day and 3-day templates, body-weight protein tables, GLP-1 specific tweaks, and creatine dosing — is in how to avoid losing muscle when losing weight.
4. Consider maintenance dosing with your clinician. A lower weekly dose, or a stretched interval, keeps some of the appetite-suppressing effect online without the cost and side-effect intensity of the maintenance dose used in the loss phase. This is off-label and not covered in trial data, but it is increasingly common practice. Have the conversation explicitly with your prescriber rather than self-tapering.
5. Use the +5 lb rule. If your 7-day average weight climbs 5 pounds above your post-loss baseline for more than two weeks, return to a mild 200 to 300 calorie daily deficit and tighten weekend eating until the baseline returns. Catching regain at +5 takes 2 to 3 weeks of effort; catching it at +15 takes a full year of effort. The broader maintenance playbook is in weight loss maintenance.

Stopping vs. tapering vs. maintenance dosing

The honest take: the “continue” arm produces the cleanest outcome on the scale, and the “stop cold” arm produces the largest regain. Most real-world decisions sit between those two, and the in-between options (taper, maintenance dosing) are where the behavioral levers above carry the most weight.

Maintenance dosing: emerging evidence and honest limits

Off-label maintenance dosing is one of the most-discussed and least-studied questions in obesity medicine right now. The pattern in clinical practice — keep a patient on semaglutide 0.5 to 1.0 mg or tirzepatide 2.5 to 5 mg once they reach goal, or stretch the interval to every 10 to 14 days — has obvious biological plausibility: STEP-4 and SURMOUNT-4 both showed that continued GLP-1 exposure at the maintenance dose holds the loss, so a lower dose should hold most of it for most patients.

What the evidence base does not yet include: long-term phase 3 trials of low-dose maintenance (STEP-4 and SURMOUNT-4 tested the full loss-phase dose, not a reduced one); optimal dose by patient phenotype (the current playbook is essentially “lowest dose that holds the loss” — pragmatic but not evidence-based at the trial level); and long-term safety at indefinite duration, although SELECT and ongoing real-world cohorts are encouraging.

Cost and coverage matter here too. Most U.S. commercial plans that cover Wegovy or Zepbound for the loss phase have no clear pathway for indefinite low-dose maintenance, and prior authorization often gets harder once a patient hits goal weight. The current landscape — including LillyDirect Zepbound vials at $349 to $549 per month as the lowest-cost branded route — is mapped in GLP-1 cost and insurance coverage.

When to talk to your clinician

Specific scenarios that warrant a clinician conversation rather than a self-managed taper:

• You have type 2 diabetes and your GLP-1 is part of your glycemic-control regimen. Stopping a GLP-1 in this context risks rebound hyperglycemia on a faster timeline than weight regain. Your endocrinologist needs to be the one routing the decision.
• You have established cardiovascular disease and are on Wegovy under its cardiovascular risk reduction indication. SELECT (Lincoff 2023) showed a 20 percent reduction in major adverse cardiovascular events; the cardiometabolic benefit fades alongside the weight effect when the drug is stopped.
• You have regained more than 5 percent of body weight despite an honest application of the lifestyle framework above. That is the threshold most obesity-medicine clinicians use to discuss restarting the medication or moving to a higher maintenance dose.
• You notice the return of binge eating or restrictive patterns during the taper. GLP-1s reduce food noise and reward-driven eating for many patients; the return of those patterns can unmask a behavioral issue that pre-dated the drug. A clinician — often paired with behavioral therapy for weight loss — should be involved sooner rather than later.
• You are post-bariatric and the GLP-1 was an adjunct after sleeve, bypass, or ESG. The interaction between surgical anatomy and GLP-1 withdrawal is patient-specific and warrants bariatric team input. See bariatric surgery overview for the broader procedure context.

For background on how the drugs themselves work, the GLP-1 weight loss overview and the GLP-1 medications compared hub cover the loss-phase trial program in depth. New pipeline drugs (CagriSema, retatrutide) may eventually change the discontinuation calculus, but their long-term withdrawal data is not yet published.

Sources